Maze Therapeutics MAZE
NASDAQ MAZE
$26.43 -0.22 (-0.83%)
At close: Oct 2, 2026 · 4:00 PM EDT

Maze Therapeutics (MAZE) Return on Capital Employed [ROCE] (2025 - 2026)

Updated

Maze Therapeutics (MAZE) posted Return on Capital Employed [ROCE] of -32.16% for Q2 2026, up 10.02 percentage points from -42.19% a year earlier and up 2.46 percentage points from the prior quarter.

Analysis

Maze Therapeutics (MAZE) Return on Capital Employed [ROCE] (2025 - 2026) Analysis & Trends

For FY2025, Maze Therapeutics' Return on Capital Employed [ROCE] came in at -48.23%.

  • The Q2 2026 figure stands as the highest quarterly Return on Capital Employed [ROCE] since Q1 2025.
  • According to Business Quant data, Return on Capital Employed [ROCE] for the three prior quarters was -34.62% (Q1 2026), -36.92% (Q4 2025) and -39.50% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROCE (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 46.74%
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 17.83%
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn 17.92%
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn 6.28%
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn 19.32%
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 9.54%
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 16.66%
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -5.97%
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 11.86%
10 Maze Therapeutics 1.47 Bn 1.47 Bn - -32.16%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -32.16%
Mar 31, 2026 -34.62%
Dec 31, 2025 -36.92%
Sep 30, 2025 -39.50%
Jun 30, 2025 -42.19%
Mar 31, 2025 18.73%
API Access

Maze Therapeutics Return on Capital Employed [ROCE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-capital-employed-%5Broce%5D&ticker=MAZE&period=max&api_key=YOUR_API_KEY